Gender specific pharmaceuticals

Abstract

The present disclosure provides a system of gender specific pharmaceuticals. The system includes a first package of a pharmaceutical for use by a male and a second package of a pharmaceutical for use by a female. The first package includes a pharmaceutical for use by a male and a first label coupled to the first package, wherein at least one of the first package and first label includes a male specifier and a recommended male dosage. The second package includes a pharmaceutical for use by a female and a second label coupled to the second package, wherein at least one of the second package and second label includes a female specifier and a recommended female dosage.

What is claimed is: 
     
         1 . A gender-specific pharmaceutical product for differentiating use for a female or male, the product comprising:
 a package containing a pharmaceutical comprising a central nervous system agent, the pharmaceutical being present in a recommended female dosage or a recommended male dosage; and   a label on the package or an insert positioned in the package,   wherein the label, the insert, or the package includes the recommended female dosage and a female-specific indicia if the pharmaceutical is present in the recommended female dosage or the recommended male dosage and a male-specific indicia if the pharmaceutical is present in the recommended male dosage, the female-specific indicia or the male-specific indicia on the label, the insert or the package differentiating use of the product for the female or the male.   
     
     
         2 . The product of  claim 1 , wherein the recommended female dosage is different than the recommended male dosage. 
     
     
         3 . The product of  claim 2 , wherein the recommended female dosage is different than the recommended male dosage based on differences between males and females in rates of drug absorption and/or metabolism. 
     
     
         4 . The product of  claim 2 , wherein the recommended female dosage is different than the recommended male dosage based on differences between males and females in at least one of temperature, diurnal changes, pH changes, hormonal changes, and susceptibility to diseases or medical conditions. 
     
     
         5 . The product of  claim 1 , wherein the pharmaceutical is provided as at least one of a tablet, capsule, powder or liquid. 
     
     
         6 . The product of  claim 1 , wherein the female-specific indicia or the male-specific indicia is in pictorial, graphic, color-coded, or text form. 
     
     
         7 . The product of  claim 1 , wherein the pharmaceutical is colored with the same color as the female-specific indicia if the pharmaceutical is present in the recommended female dosage or as the male-specific indicia if the pharmaceutical is present in the recommended male dosage. 
     
     
         8 . The product of  claim 1 , further comprising an RFID tag associated with the package. 
     
     
         9 . The product of  claim 1 , wherein the label, the insert or the package provides a recommended time period between administration of the recommended female dosage if the pharmaceutical is present in the recommended female dosage, or the recommended male dosage if the pharmaceutical is present in the recommended male dosage. 
     
     
         10 . The product of  claim 1 , wherein the recommended time period is different if the pharmaceutical is present in the recommended female dosage then the recommended time period if the pharmaceutical is present in the recommended male dosage. 
     
     
         11 . The product of  claim 1 , wherein the central nervous system agent is a central nervous system depressant. 
     
     
         12 . The product of  claim 1 , wherein the central nervous system depressant is a sedative. 
     
     
         13 . A patient group-specific pharmaceutical product for differentiating use for a first patient group or a second patient group, the product comprising:
 a package containing a pharmaceutical comprising a central nervous system agent, the pharmaceutical being present in a recommended first patient group dosage or a recommended second patient group dosage; and   a label on the package or an insert positioned in the package,   wherein the label, the insert, or the package includes the recommended first patient group dosage and a first patient group-specific indicia if the pharmaceutical is present in the recommended first patient group dosage or the recommended second patient group dosage and a second patient group-specific indicia if the pharmaceutical is present in the recommended second patient group dosage, the first patient group-specific indicia or the second patient group-specific indicia on the label, the insert or the package differentiating use of the product for the first patient group or the second patient group.   
     
     
         14 . The product of  claim 13 , wherein the recommended first patient group dosage is different than the recommended second patient group dosage. 
     
     
         15 . The product of  claim 14 , wherein the recommended first patient group dosage is different than the recommended second patient group dosage based on differences between the first patient group and the second patient group in rates of drug absorption and/or metabolism. 
     
     
         16 . The product of  claim 14 , wherein the recommended first patient group dosage is different than the recommended second patient group dosage based on differences between the first patient group and the second patient group in at least one of temperature, diurnal changes, pH changes, hormonal changes, and susceptibility to diseases or medical conditions. 
     
     
         17 . The product of  claim 13 , wherein the pharmaceutical is provided as at least one of a tablet, capsule, powder or liquid. 
     
     
         18 . The product of  claim 13 , wherein the first patient group-specific indicia or the second patient group-specific indicia is in pictorial, graphic, color-coded, or text form. 
     
     
         19 . The product of  claim 13 , wherein the pharmaceutical is colored with the same color as the first patient group-specific indicia if the pharmaceutical is present in the recommended first patient group dosage or as the second patient group-specific indicia if the pharmaceutical is present in the recommended second patient group dosage. 
     
     
         20 . The product of  claim 13 , further comprising an RFID tag associated with the package. 
     
     
         21 . The product of  claim 13 , wherein the label, the insert or the package provides a recommended time period between administration of the recommended first patient group dosage if the pharmaceutical is present in the recommended first patient group dosage, or the recommended second patient group dosage if the pharmaceutical is present in the recommended second patient group dosage. 
     
     
         22 . The product of  claim 13 , wherein the recommended time period is different if the pharmaceutical is present in the recommended first patient group dosage then the recommended time period if the pharmaceutical is present in the recommended second patient group dosage. 
     
     
         23 . The product of  claim 13 , wherein the recommended first patient group dosage is different from the recommended second patient group dosage by 10 percent or more. 
     
     
         24 . The product of  claim 13 , wherein the recommended first patient group dosage or the recommended second patient group dosage includes an initial dosage. 
     
     
         25 . The product of  claim 13 , wherein the central nervous system agent is a central nervous system depressant. 
     
     
         26 . The product of  claim 13 , wherein the central nervous system depressant is a sedative. 
     
     
         27 . A method of packaging the gender-specific pharmaceutical product of  claim 1  for differentiating use of the product for a female or a male, the method comprising:
 preparing the package, the label, or the insert to include the female-specific indicia or the male-specific indicia on the package, the label, or the insert to differentiate use of the product for the female or the male. 
 
     
     
         28 . A method of packaging the gender-specific pharmaceutical product of  claim 13  for differentiating use of the product for a first patient group or a second patient group, the method comprising:
 preparing the package, the label, or the insert to include the first patient group-specific indicia or the second patient group-specific indicia on the package, the label, or the insert to differentiate use of the product for the first patient group or the second patient group.